# Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer

> **NCT00046527** · PHASE3 · COMPLETED · sponsor: **Celgene Corporation** · enrollment: 460 (—)

## Conditions studied

- Breast Neoplasms
- Metastases, Neoplasm

## Interventions

- **DRUG:** ABI-007

## Key facts

- **NCT ID:** NCT00046527
- **Lead sponsor:** Celgene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-06
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 460 (—)
- **Last updated:** 2006-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00046527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00046527, "Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00046527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*